Response to Hobai
- PMID: 39348306
- PMCID: PMC11785492
- DOI: 10.14309/ajg.0000000000003079
Response to Hobai
Conflict of interest statement
Potential Conflicts of Interest:
Walter Chan served on the advisory board for Phathom Pharmaceuticals, Sanofi Pharmaceuticals, and Regeneron Pharmaceuticals. No other authors have potential conflicts of interest to disclose.
Comment on
- Am J Gastroenterol.
-
Gastric Motility Assays May Not Capture the Entire Clinical Picture in Patients Using Glucagon-Like Peptide-1 Receptor Agonists.Am J Gastroenterol. 2025 Feb 1;120(2):482. doi: 10.14309/ajg.0000000000002949. Epub 2024 Aug 9. Am J Gastroenterol. 2025. PMID: 39120044 No abstract available.
References
-
- Hobai IA. Gastric motility assays may not capture the entire clinical picture in patients using GLP-1 receptor agonists. Am J Gastroenterol 2024: This issue. - PubMed
-
- Yeo YH, Gaddam S, Ng WH, et al. Increased Risk of Aspiration Pneumonia Associated With Endoscopic Procedures Among Patients With Glucagon-like Peptide 1 Receptor Agonist Use. Gastroenterology 2024. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
